Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial
- Gotta, V
- Widmer, N
- Decosterd, L A
- Chalandon, Yves
- Heim, D
- Gregor, M
- Benz, R
- Leoncini-Franscini, L
- Baerlocher, G M
- Duchosal, M A
- Csajka, C
- Buclin, Thierry
Publication date
January 2014
DOI Publisher
Springer Science and Business Media LLCAbstract
This study assessed whether a cycle of "routine" therapeutic drug monitoring (TDM) for imatinib dosage individualization, targeting an imatinib trough plasma concentration (C min) of 1,000 ng/ml (tolerance: 750-1,500 ng/ml), could improve clinical outcomes in chronic myelogenous leukemia (CML) patients, compared with TDM use only in case of problems ("rescue" TDM)
Add to ORKG